NEW YORK, Jan 2, 2026, 2:49 PM ET — Regular session
- Nuvation Bio shares were down about 6.8% in afternoon trade after an early jump.
- The move outpaced broader biotech funds, which were only modestly lower.
- Investors are watching for the next update on IBTROZI launch traction and clinical milestones.
Shares of Nuvation Bio Inc fell about 6.8% to $8.35 in afternoon trading on Friday, after opening at $8.97 and swinging between $9.13 and $8.30. About 3.3 million shares had changed hands.
The decline stood out against a softer but steadier biotech tape. The SPDR S&P Biotech ETF was down about 0.7% and iShares Nasdaq Biotechnology ETF slipped about 0.2%, while the S&P 500 ETF was modestly higher and small caps outperformed.
The stock’s slide comes as investors recalibrate risk in the first U.S. session of 2026, with strategists warning valuations leave less room for disappointment. “Stocks trade expensive on 18 of 20 measures, and we see elevated risks to the index level in the near term,” Bank of America equity and quant strategist Savita Subramanian wrote in a note, while markets also look ahead to next week’s U.S. labor-market data. Reuters
There was no fresh regulatory disclosure to point to. Nuvation Bio’s most recent SEC filing was dated Dec. 3, according to the agency’s EDGAR feed, and its latest quarterly report was filed on Nov. 3.
The company is best known on Wall Street for IBTROZI, its once-daily oral lung-cancer drug, which won U.S. approval in June 2025 for ROS1-positive non-small cell lung cancer — a small subset of cases driven by a ROS1 gene fusion. Competing ROS1 drugs include Bristol Myers Squibb’s Augtyro, Pfizer’s Xalkori and Roche’s Rozlytrek, Reuters has reported.
Investors have been watching early commercial signals closely as Nuvation shifts from development-stage headlines to launch execution. In its last quarterly update, the company said it started 204 patients on IBTROZI during the third quarter of 2025.
Beyond the commercial launch, traders have focused on whether Nuvation can broaden its evidence base in earlier settings. The company said in September 2025 it enrolled the first patient in TRUST-IV, a Phase 3 study evaluating IBTROZI in an adjuvant setting for ROS1-positive early-stage disease.
Nuvation’s other closely followed program is safusidenib, its mutant IDH1 inhibitor for glioma. In December, the company announced publication of positive Phase 2 results in grade 2 IDH1-mutant glioma and said it had reached alignment with the FDA on modifying its ongoing G203 study into a pivotal trial in high-grade gliomas.
Nuvation describes itself as a global biopharmaceutical company focused on oncology, with programs including taletrectinib, safusidenib and earlier-stage assets.
For Friday’s session, the chart did most of the talking. The stock flipped from an early high near $9.13 to trade closer to its intraday low, leaving technicians watching the session low as near-term support and the morning peak as the first resistance zone.
Near term, investors are likely to stay keyed on any updates that sharpen the launch picture — prescriptions, payer coverage and the cadence of new patient starts — as well as timelines for additional data from the TRUST program and the next steps for safusidenib.
